Quick Answer
Decoy Therapeutics Inc. reported Earnings Per Share Diluted of $129.10 (loss) per share for the year ending 2025.
- Decoy Therapeutics Inc. showed a decrease of -85.6% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Decoy Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $0.13 (loss) per share | Q3 2020: $0.10 (loss) per share | Q1 2021: $0.06 (loss) per share | Q2 2021: $0.07 (loss) per share | Q3 2021: $2.09 (loss) per share | Q1 2022: $3.30 (loss) per share | Q2 2022: $2.20 (loss) per share | Q3 2022: $6.41 (loss) per share | Q1 2023: $2.23 (loss) per share | Q2 2023: $11.45 (loss) per share | Q3 2023: $5.21 (loss) per share | Q1 2024: $3.27 (loss) per share | Q2 2024: $2.37 (loss) per share | Q3 2024: $11.38 (loss) per share | Q1 2025: $1.03 (loss) per share | Q2 2025: $0.45 (loss) per share | Q3 2025: $1.81 (loss) per share.
- Over the full 6 years of available data (2020 to 2025), Decoy Therapeutics Inc.'s Earnings Per Share Diluted has declined by 25,720.0%.
- Historical annual values: Fiscal year 2025: $129.10 (loss) per share | Fiscal year 2024: $69.54 (loss) per share | Fiscal year 2023: $30.74 (loss) per share | Fiscal year 2022: $14.88 (loss) per share | Fiscal year 2021: $7.72 (loss) per share | Fiscal year 2020: $0.50 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: